1027232-57-0Relevant articles and documents
A novel celecoxib analog UTX-121 inhibits HT1080 cell invasion by modulating membrane-type 1 matrix metalloproteinase
Yamahana, Hirari,Takino, Takahisa,Endo, Yoshio,Yamada, Hisatsugu,Suzuki, Takeshi,Uto, Yoshihiro
, p. 137 - 144 (2020)
We designed and synthesized a celecoxib derivative UTX-121 to enhance its anti-tumor activity. Similar to celecoxib, this compound could also inhibit matrix metalloproteinase (MMP)-9 activity. In addition, UTX-121 suppressed membrane-type 1 MMP (MT1-MMP)-
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif
Yang, Jinyu,Cheng, Gaoliang,Xu, Qihao,Luan, Shenglin,Wang, Shuxiang,Liu, Dan,Zhao, Linxiang
, p. 1418 - 1425 (2018)
In recent years, inhibition of HDAC6 became a promising therapeutic strategy for the treatment of cancer and HDAC6 inhibitors were considered to be potent anti-cancer agents. In this work, celecoxib showed moderate degree of HDAC6 inhibition activity and selectivity in preliminary enzyme inhibition activity assay. A series of hydroxamic acid derivatives bearing phenylpyrazol moiety were designed and synthesized as HDAC6 inhibitors. Most compounds showed potent HDAC6 inhibition activity. 11i was the most selective compound against HDAC6 with IC50 values of 0.020 μM and selective factor of 101.1. Structure-activity relationship analysis indicated that locating the linker group at 1′ of pyrazol gave the most selectivity. The most compounds 11i (GI50 = 3.63 μM) exhibited 6-fold more potent than vorinostat in HepG2 cells. Considering of the high selectivity against HDAC6 and anti-proliferation activity, such compounds have potential to be developed as anti-cancer agents.
With anti-tumor activity of phenyl hydroxamic acid compounds and use thereof (by machine translation)
-
Paragraph 0052; 0053; 0054, (2018/04/01)
The invention belongs to the field of medical technology, relates to a with anti-tumor activity of phenyl hydroxamic acid compounds, and in particular to the 3 (5) - substituted phenyl - 5 (3) - substituted pyrazole fragment phenyl hydroxamic acid compounds, and their pharmaceutically acceptable salt, hydrate, and the compound as the active ingredient of the pharmaceutical composition, and the preparation of histone deacetylase inhibitors and their use for the treatment and/or prevention of cancer. The compound of the following structure: wherein R1 Independently selected from one or more of the following substituents: halogen, (C1 - C4) alkyl, dioxo methylene; R2 Is independently selected from (C1 - C4) alkyl, halo (C1 - C4) alkyl, substituted or unsubstituted phenyl, said substituent is (C1 - C4) alkyl; n is 0 - 2 is an integer between. (by machine translation)
Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer
Gao, Mingzhang,Wang, Min,Miller, Kathy D.,Zheng, Qi-Huang
, p. 4760 - 4767 (2011/11/04)
The enzyme cyclooxygenase-2 (COX-2) is overexpressed in a variety of malignant tumors. This study was designed to develop new radiotracers for imaging of COX-2 in cancer using biomedical imaging technique positron emission tomography (PET). Carbon-11-labeled celecoxib derivatives, [11C]4a-c and [11C]8a-d, were prepared by O-[11C] methylation of their corresponding precursors using [11C]CH3OTf under basic conditions and isolated by a simplified solid-phase extraction (SPE) method in 52 ± 2% (n = 5) and 57 ± 3% (n = 5) radiochemical yields based on [11C]CO2 and decay corrected to end of bombardment (EOB). The overall synthesis time from EOB was 23 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 277.5 ± 92.5 GBq/μmol (n = 5). The IC50 values to block COX-2 for known compounds celecoxib (4d), 4a and 4c were 40, 290 and 8 nM, respectively, and preliminary findings from in vitro biological assay indicated that the synthesized new compounds 4b and 8a-d display similar strong inhibitory effectiveness in the MDA-MB-435 human cancer cell line in comparison with the parent compound 4d. These results encourage further in vivo evaluation of carbon-11-labeled celecoxib derivatives as new potential PET radiotracers for imaging of COX-2 expression in cancer.
Nitrooxymethyl-substituted analogues of celecoxib: Synthesis and pharmacological characterization
Boschi, Donatella,Lazzarato, Loretta,Rolando, Barbara,Filieri, Andrea,Cena, Clara,Di Stilo, Antonella,Fruttero, Roberta,Gasco, Alberto
experimental part, p. 369 - 379 (2010/04/23)
Nitrooxymethyl-substituted analogues of celecoxib were synthesized and tested for their cyclooxygenase (COX)-inhibiting, vasodilator, and anti-aggregatory activities, as well as for their metabolic stability in human serum and whole blood. The results showed their potency and selectivity in inhibiting the COX isoforms, evaluated in whole human blood, as well as their anti-aggregatory activity to depend closely on the position at which the NO-donor moiety is introduced. All products dilated rat aorta strips precontracted with phenylephrine in a dose-dependent manner through a cGMP-dependent mechanism. They were stable in human serum while, in blood, they were metabolically transformed, principally to the related alcohols.
